Triple combination cures most hepatitis C patients with prior DAA treatment failure

Triple combination cures most hepatitis C patients with prior DAA treatment failure
Liz Highleyman
Produced in collaboration with hivandhepatitis.com
Published: 28 April 2017

NAM aidsmap

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination being developed by Merck, researchers reported at the International Liver Congress last week in Amsterdam.

Direct-acting antivirals (DAAs) have revolutionised the treatment of chronic hepatitis C virus (HCV) infection, with cure rates approaching 100% for most groups of patients. But better options are still needed for people who do not respond to a first attempt at interferon-free therapy and may have drug-resistant virus.
Continue reading...

Meeting Updates
Updates On This Blog

Hep C 5-minute videos - Summary Of The International Liver Congress™ (ILC) 2017

On this page of the blog visitors are provided with an index of links pointing to comprehensive coverage of the meeting.  Start by viewing a short video series over at Practice Point presented by Dr. Tran, highlights include clinical studies on new antiviral therapy, data on drug toxicity/adverse events, drug interactions, and strategies for HCV management. On May 1, ViralEd will launch: The Advances in Chronic Hepatitis C: Management and Treatment, a comprehensive program featuring HCV experts reviewing and discussing the most important studies on chronic hepatitis C presented at EASL 2017. Other videos include EASL press conference, and opening ceremony.

Coverage

infohep
NAM aidsmap
Clinical Care Options
HIV and Hepatitis
Hep